Clinical Trial Update: BKM120 in Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of buparlisib (BKM120) for metastatic castration-resistant prostate cancer was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Buparlisib (buparlisib)

Snippet

Sponsor: Andrew J. Armstrong, MD | Conditions: Prostate Cancer, Metastatic (Spread to Other Areas of the Body) | Phase 2 | Status: TERMINATED | Results posted: 2017-04-07